Project Grant R01HL182015
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $705,063 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, for the project "Personalized Risk Prediction and Mechanistic Profiling of Cardiac Allograft Vasculopathy". The award period runs from Aug 15, 2025 to May 31, 2029. The project aims to develop advanced digital...
- This $240,552 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research project titled "Unraveling the Cell Networks in Bone Marrow Through Transcriptomic and Epigenetic Profiling" at the University of Pennsylvania. The project aims to generate a comprehensive single-cell transcriptomic and regulomic map of human bone marrow cells and experimentally establish the mesenchymal cell hierarchy in human bone....
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) aims to determine if cancer directly promotes cardiovascular disease and explore potential therapies. The $1,102,957 award to The Leland Stanford Junior University, commencing on April 15, 2025 and scheduled for completion on January 31, 2032, will fund a multidisciplinary research program across population genetics, cardio-oncology, and translational medicine. The...
- This $1,137,498.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to investigate the regulatory mechanisms involved in cardiac maturation. The primary awardee, The Trustees of the University of Pennsylvania, will conduct this work between April 1, 2025 and March 31, 2032. The research aims to address three key questions: 1) whether naturally-occurring variants in human cardiomyocyte genomic...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,513,201 in funding to The Trustees of the University of Pennsylvania to research excess cardiovascular inflammation in tuberculosis (TB) and HIV. The overarching hypothesis is that TB promotes pulmonary inflammation leading to subclinical vascular pathology, increasing the risk of major cardiovascular events in TB survivors. The research will investigate...
- The federal Project Grant award of $108,512 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The award will fund research to determine how inflammation is regulated in Runx1-Familial Platelet Disorder (Runx1-FPD), a genetic disorder that increases the risk of hematologic malignancies. The research aims to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $812,403.00 to The Trustees of the University of Pennsylvania to investigate the mechanisms by which cardiac stereotactic body radiation therapy (CSBRT) impacts ventricular tachycardia (VT) in a large animal model of chronic myocardial infarction. The research aims to better understand the structural and electrophysiologic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $174,420 to The Trustees of the University of Pennsylvania to conduct research aimed at improving lung transplantation outcomes. The key objectives are to investigate the impact of centralizing deceased organ donor management at specialized Donor Care Units (DCUs) and assess the consequences for diverse stakeholders in the national donation and transplantation...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a study examining the link between stressful life events and cardiovascular disease (CVD) risk. The $156,858 award, granted on February 1, 2025, will enable the University of Pittsburgh to utilize deidentified data from 656 healthy adults to investigate how brain and behavioral measures of negative affect and cognitive reappraisal...
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
This $738,472 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), to The Trustees of the University of Pennsylvania. The grant supports a research project titled "CARDIOVASCULAR RISK PREDICTION AND REDUCTION IN MEN WITH PROSTATE CANCER". The objective is to develop accurate cardiovascular disease (CVD) risk prediction models for men with prostate cancer, as existing tools do not account for cancer-specific factors that influence CVD risk in this population. The research aims to improve CVD management and overall health outcomes for men with prostate cancer through personalized, risk-based preventive strategies. The award period runs from September 25, 2025 through August 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $21.8k | 9/22/25 | ||
| Not listed | $716.7k | 9/19/25 |